Biogen Asks For Yet More Patience As Leqembi Sales Begin Slow Ascent
Skyclarys From Reata A More Immediate Revenue Source
Executive Summary
CEO Chris Viehbacher outlined progress Biogen made in the third quarter, including full approval for the Eisai-partnered Alzheimer’s drug Leqembi, but recent wins will take time to make up for long-term revenue declines.